STOCK TITAN

Marinus Pharmaceuticals Inc - MRNS STOCK NEWS

Welcome to our dedicated news page for Marinus Pharmaceuticals (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marinus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marinus Pharmaceuticals's position in the market.

Rhea-AI Summary
Marinus Pharmaceuticals expects estimated net product revenue of $5-5.2 million for Q3 2023 from ZTALMY. Cash runway extended into Q4 2024 with projected cash of $170-175 million as of September 30, 2023. Enrollment in Phase 3 RAISE trial on track for topline data in Q1 2024. Ganaxolone development in RAISE trial funded in part by BARDA. TSC trial anticipated to enroll 128 patients with topline data expected in mid-2024. Total cash, cash equivalents, and short-term investments projected to be between $170-175 million at the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.88%
Tags
none
-
Rhea-AI Summary
Marinus Pharmaceuticals announces speakers for Investor & Analyst Event on September 19. Key opinion leaders will discuss clinical experience treating patients with seizure disorders. In-person attendance open to research analysts and institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
none
-
Rhea-AI Summary
Marinus Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.46%
Tags
none
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. will host a hybrid Investor & Analyst Event on September 19 to discuss the Company's clinical pipeline progress, strategic initiatives, and business outlook. In-person attendance is open to invited research analysts and institutional investors, while others can watch the live video webcast. Questions can be submitted through the webcast platform. A replay of the webcast will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.63%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.1%
Tags
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that the European Commission has approved ZTALMY (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age, with continued use for patients 18 years and older. The approval is based on positive data from the Phase 3 Marigold trial, showing a median 30.7% reduction in 28-day major motor seizure frequency for patients treated with ZTALMY compared to a median 6.9% reduction for those receiving placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
Marinus Pharmaceuticals Inc

Nasdaq:MRNS

MRNS Rankings

MRNS Stock Data

413.08M
42.76M
1.57%
98.62%
6.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Radnor

About MRNS

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides